Company intelligence / Profile preview

ECG-Excellence

Nieuwerbrug, Zuid-Holland, Netherlandsecg-excellence.com ↗

Ownership: Private
Employees: ~3
Development stage: Commercial

Overview

CineECG has demonstrated high accuracy in distinguishing normal from abnormal heart performance using standard 12-lead ECG data. In primary care, up to 95% accuracy was achieved. For ischemia detection, CineECG improved classification rates by over 25%. In COVID patient studies, the system correctly classified up to 98% of normal and 94% of abnormal cases compared to expert review. The technology aims to reduce over-diagnosis costs by up to 35%, while fitting into existing clinical workflows and reimbursement structures.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Physiological Monitoring

Drug pipeline

3 assets

CineECG

Commercial

Indications: ECG interpretation, Heart conduction disorders

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on ECG-Excellence.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ECG-Excellence.

Explore the full profile